Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Millennium Oncology
mi
from
Hollywood, FL
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Millennium Oncology
mi
from
Hollywood, FL
Click here to add this to my saved trials
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute SCRI
mi
from
Chattanooga, TN
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute SCRI
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin
The Ability of Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Standard Chemotherapy Regimens Containing Doxorubicin
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Hospital
mi
from
Indianapolis, IN
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin
The Ability of Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Standard Chemotherapy Regimens Containing Doxorubicin
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin
The Ability of Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Standard Chemotherapy Regimens Containing Doxorubicin
Status: Enrolling
Updated:  12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin
The Ability of Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Standard Chemotherapy Regimens Containing Doxorubicin
Status: Enrolling
Updated: 12/31/1969
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)
Status: Enrolling
Updated:  12/31/1969
Teton Cancer Institute
mi
from
Idaho Falls, ID
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)
Status: Enrolling
Updated: 12/31/1969
Teton Cancer Institute
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Early Detection of Breast Cancer in Women With Suspicious Mammograms
Early Detection of Breast Cancer in Women With Suspicious Mammograms
Status: Enrolling
Updated:  12/31/1969
Dorothy G Hoefer Comprehensive Breast Center
mi
from
Newport News, VA
Early Detection of Breast Cancer in Women With Suspicious Mammograms
Early Detection of Breast Cancer in Women With Suspicious Mammograms
Status: Enrolling
Updated: 12/31/1969
Dorothy G Hoefer Comprehensive Breast Center
mi
from
Newport News, VA
Click here to add this to my saved trials
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Status: Enrolling
Updated:  12/31/1969
Medical Oncology Associates
mi
from
Spokane, WA
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Status: Enrolling
Updated: 12/31/1969
Medical Oncology Associates
mi
from
Spokane, WA
Click here to add this to my saved trials
Implementing Systematic Distress Screening in Breast Cancer
Implementing Systematic Distress Screening in Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Anaheim Medical Center
mi
from
Anaheim, CA
Implementing Systematic Distress Screening in Breast Cancer
Implementing Systematic Distress Screening in Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Anaheim Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Implementing Systematic Distress Screening in Breast Cancer
Implementing Systematic Distress Screening in Breast Cancer
Status: Enrolling
Updated:  12/31/1969
South Bay - Harbor City Medical Center
mi
from
Harbor City, CA
Implementing Systematic Distress Screening in Breast Cancer
Implementing Systematic Distress Screening in Breast Cancer
Status: Enrolling
Updated: 12/31/1969
South Bay - Harbor City Medical Center
mi
from
Harbor City, CA
Click here to add this to my saved trials
Implementing Systematic Distress Screening in Breast Cancer
Implementing Systematic Distress Screening in Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Los Angeles Medical Center
mi
from
Los Angeles, CA
Implementing Systematic Distress Screening in Breast Cancer
Implementing Systematic Distress Screening in Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Study Evaluating HKI-272 in Tumors
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
LAC/USC Medical Center, USC/Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
LAC/USC Medical Center, USC/Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope National Medical Center
mi
from
Pasadena, CA
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Pasadena, CA
Click here to add this to my saved trials
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Maryland, University of Maryland Medical Center
mi
from
Baltimore, MD
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Maryland, University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Duke University, Duke University Medical Center
mi
from
Durham, NC
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Duke University, Duke University Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Chinese Nanjing Bayi Hospital
mi
from
Nanjing,
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Chinese Nanjing Bayi Hospital
mi
from
Nanjing,
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Scripps, Clinic General
mi
from
La Jolla, CA
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Scripps, Clinic General
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sharp Memorial Hospital
mi
from
San Diego, CA
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
mi
from
Boston, MA
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mid-Michigan Physicians-HOS Division
mi
from
Lansing, MI
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mid-Michigan Physicians-HOS Division
mi
from
Lansing, MI
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Institut Jules Bordet Unite du Chimiotherapie
mi
from
Brussels,
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Institut Jules Bordet Unite du Chimiotherapie
mi
from
Brussels,
Click here to add this to my saved trials
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
Status: Enrolling
Updated:  12/31/1969
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
Status: Enrolling
Updated: 12/31/1969
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Southwest Cancer Care
mi
from
Murrieta, CA
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Southwest Cancer Care
mi
from
Murrieta, CA
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Uc Irvine Medical Center
mi
from
Orange, CA
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Uc Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Aptium Oncology/Comprehensive Cancer Center at Desert Regional Medical Center
mi
from
Palm Springs, CA
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Aptium Oncology/Comprehensive Cancer Center at Desert Regional Medical Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Redwood Regional Medical Group, Inc.
mi
from
Santa Rosa, CA
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Redwood Regional Medical Group, Inc.
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates, PC
mi
from
Stamford, CT
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates, PC
mi
from
Stamford, CT
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Robert R. Carroll, MD, PA
mi
from
Gainesville, FL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Robert R. Carroll, MD, PA
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Jacksonville, FL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates
mi
from
Loxahatchee Groves, FL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Research Institute
mi
from
Miami, FL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of Florida
mi
from
Orlando, FL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials